Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2018 1
2022 4
2023 3
2024 1
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Lipid nanoparticle mediated delivery of Anti-CD19 CAR mRNA to umbilical cord blood NK cells for targeting CD19⁺ primary B-ALL cells.
Salehi-Shadkami H, Sedghi M, Tavoosi S, Alimohammadi M, Alimohammadi R, Barkhordar M, Mofayezi A, Modaresi MS, Vaezi M, Dehghanizadeh S, Ahmadvand M, Khoddami V. Salehi-Shadkami H, et al. Among authors: alimohammadi m. Curr Res Transl Med. 2026 Jan-Mar;74(1):103563. doi: 10.1016/j.retram.2025.103563. Epub 2025 Dec 17. Curr Res Transl Med. 2026. PMID: 41422708
Combining ablative radiotherapy and anti CD47 monoclonal antibody improves infiltration of immune cells in tumor microenvironments.
Rostami E, Bakhshandeh M, Ghaffari-Nazari H, Alinezhad M, Alimohammadi M, Alimohammadi R, Mahmoodi Chalbatani G, Hejazi E, Webster TJ, Tavakkol-Afshari J, Jalali SA. Rostami E, et al. Among authors: alimohammadi m. PLoS One. 2022 Aug 26;17(8):e0273547. doi: 10.1371/journal.pone.0273547. eCollection 2022. PLoS One. 2022. PMID: 36018888 Free PMC article.
SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN®, induces robust humoral and cellular immunity in mice and non-human primates.
Alimohammadi R, Porgoo M, Eftekhary M, Kiaie SH, Ansari Dezfouli E, Dehghani M, Nasrollahi K, Malekshahabi T, Heidari M, Pouya S, Alimohammadi M, Sattari Khavas D, Modaresi MS, Ghasemi MH, Ramyar H, Mohammadipour F, Hamzelouei F, Mofayezi A, Mottaghi SS, Rahmati A, Razzaznian M, Tirandazi V, Tat M, Borzouee F, Sadeghi H, Haji Mohammadi M, Rastegar L, Safar Sajadi SM, Ehsanbakhsh H, Bazmbar H, Baghernejadan Z, Shams Nouraei M, Pazooki P, Pahlavanneshan M, Alishah K, Nasiri F, Mokhberian N, Mohammadi SS, Akar S, Niknam H, Azizi M, Ajoudanian M, Moteallehi-Ardakani MH, Mousavi Shaegh SA, Ramezani R, Salimi V, Moazzami R, Hashemi SM, Dehghanizadeh S, Khoddami V. Alimohammadi R, et al. Among authors: alimohammadi m. NPJ Vaccines. 2022 Sep 2;7(1):105. doi: 10.1038/s41541-022-00528-3. NPJ Vaccines. 2022. PMID: 36056015 Free PMC article.
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
Salehi M, Alavi Darazam I, Nematollahi A, Alimohammadi M, Pouya S, Alimohammadi R, Khajavirad N, Porgoo M, Sedghi M, Mahdi Sepahi M, Azimi M, Hosseini H, Mahmoud Hashemi S, Dehghanizadeh S, Khoddami V. Salehi M, et al. Among authors: alimohammadi m. Int Immunopharmacol. 2024 Jun 15;134:112192. doi: 10.1016/j.intimp.2024.112192. Epub 2024 May 17. Int Immunopharmacol. 2024. PMID: 38761778 Clinical Trial.